Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib

Rearrangement of anaplastic lymphoma kinase (ALK) gene is detected in approximately 5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors targeting ALK have significantly improved the prognosis of these patients. However, most patients experienced disease progression within a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rijavec, Erika, Biello, Federica, Indini, Alice, Grossi, Francesco, Genova, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786362/
https://www.ncbi.nlm.nih.gov/pubmed/35082536
http://dx.doi.org/10.2147/CPAA.S284850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786362/
https://www.ncbi.nlm.nih.gov/pubmed/35082536
http://dx.doi.org/10.2147/CPAA.S284850

Ejemplares similares